MMP9, matrix metallopeptidase 9, 4318

N. diseases: 1337; N. variants: 31
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0856169
Disease: Endothelial dysfunction
Endothelial dysfunction
0.060 Biomarker phenotype BEFREE Expression level of multiple markers implicated in inflammation (tumor necrosis factor (TNF)-α, interleukin (IL)-1β, IL-4, IL-6, IL-8, IL-10; metalloproteinase MMP-9) and markers of endothelial dysfunction (I-CAM and V-CAM) was determined from lung tissues mRNA using RT-PCR. 30056108 2018
CUI: C0856169
Disease: Endothelial dysfunction
Endothelial dysfunction
0.060 Biomarker phenotype BEFREE C-reactive protein, a marker of intimal thickening of the myeloid-related protein 8/14 heterodimer, monocyte chemotactic protein 1, interleukin-15, the cytotoxic mediator, granulysin, and the matrix metalloproteinase 9 could be valuable, single, fast, and non-invasive laboratory tools for ED deterioration degree assessment. 29685202 2018
CUI: C0856169
Disease: Endothelial dysfunction
Endothelial dysfunction
0.060 AlteredExpression phenotype BEFREE Endothelial dysfunction was associated with elevated levels of fibroblast growth factor basic, matrix metalloproteinase 9 and nephroblastoma overexpressed gene proteins. 29466879 2018
CUI: C0856169
Disease: Endothelial dysfunction
Endothelial dysfunction
0.060 Biomarker phenotype BEFREE The aim of this study was to evaluate the association of MMP-2 and MMP-9 with markers of endothelial dysfunction, soluble E-selectin and brachial flow-mediated dilatation; several biochemical risk factors of CVD; and thrombotic incidents in children with ESRD. 29891747 2018
CUI: C0856169
Disease: Endothelial dysfunction
Endothelial dysfunction
0.060 Biomarker phenotype BEFREE Visfatin may induce the expression of pro-angiogenic factors, such as VEGF and MMP-9, in women with PCOS, inplying gradually development of endothelial dysfunction. 28300464 2017
CUI: C0856169
Disease: Endothelial dysfunction
Endothelial dysfunction
0.060 AlteredExpression phenotype BEFREE In contrast, IVA maintained and PT improved cerebral endothelial nitric oxide synthase-dependent flow-mediated dilation and wall compliance, and both interventions reduced MMP-9 activity (P < 0.05); METO worsened endothelial dysfunction and compliance and did not reduce MMP-9 activity. 21926346 2011